Avalo Therapeutics, Inc. (AVTX)
| Market Cap | 495.82M +833.7% |
| Revenue (ttm) | 59,000 -86.6% |
| Net Income | -84.74M |
| EPS | -5.36 |
| Shares Out | 26.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,996 |
| Open | 18.76 |
| Previous Close | 19.01 |
| Day's Range | 18.44 - 19.00 |
| 52-Week Range | 3.39 - 24.27 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 45.20 (+143.53%) |
| Earnings Date | May 13, 2026 |
About AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Financial Performance
In 2025, Avalo Therapeutics's revenue was $59,000, a decrease of -86.62% compared to the previous year's $441,000. Losses were -$78.26 million, 122.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $45.2, which is an increase of 143.53% from the latest price.
News
Avalo Therapeutics price target lowered to $34 from $40 at Wedbush
Wedbush lowered the firm’s price target on Avalo Therapeutics (AVTX) to $34 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported first quarter…
Avalo Therapeutics price target raised to $45 from $39 at Mizuho
Mizuho raised the firm’s price target on Avalo Therapeutics (AVTX) to $45 from $39 and keeps an Outperform rating on the shares post the Q1 report. The company continues to…
Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Avalo Therapeutics (AVTX) to $35 from $40 and keeps a Buy rating on the shares. The LOTUS results showed that abdakibart is…
Avalo Therapeutics price target lowered to $55 from $62 at Citizens
Citizens analyst Jason Butler lowered the firm’s price target on Avalo Therapeutics (AVTX) to $55 from $62 and keeps an Outperform rating on the shares. Positive Phase 2 LOTUS results…
Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)
“The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent clinical response across both HiSCR75 and HiSCR50 endpoints, mark the beginning of a…
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-m...
Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler
Piper Sandler raised the firm’s price target on Avalo Therapeutics (AVTX) to $60 from $48 and keeps an Overweight rating on the shares. The firm notes shares traded-up about 60%…
Avalo Therapeutics price target raised to $62 from $52 at Citizens
Citizens raised the firm’s price target on Avalo Therapeutics (AVTX) to $62 from $52 and keeps an Outperform rating on the shares. Avalo Therapeutics reported positive Phase 2 results for…
Avalo Therapeutics 19.73M share Spot Secondary priced at $17.75
The deal range was $17.25-$17.75. Leerink, TD Cowen and BofA acted as joint book running managers for the offering.
Avalo Therapeutics price target raised to $58 from $40 at BTIG
BTIG raised the firm’s price target on Avalo Therapeutics (AVTX) to $58 from $40 and keeps a Buy rating on the shares. The firm is citing the company’s announcement of…
Why Is Avalo Therapeutics Stock (AVTX) Up Today?
Avalo Therapeutics stock was up on Wednesday alongside a public offering.
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-m...
Avalo Therapeutics announces common stock and warrants offering, no amount given
Avalo Therapeutics (AVTX) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to…
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-m...
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated in...
Avalo Therapeutics announces AlmataBio buyout option, amendment agreement
Avalo Therapeutics (AVTX) announced that it has entered into a milestone buyout option and amendment agreement related to the company’s prior acquisition of AlmataBio in March of 2024. Pursuant to…
Avalo Therapeutics Purchases Optional Milestone Buyout
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune...
Avalo Therapeutics initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $48 price target The LOTUS Phase 2 trial readout due around May or June “will likely dictate…
Avalo Therapeutics initiated with an Outperform at Citizens
Citizens analyst Jason Butler initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $52 price target The company is developing abdakibart with an optimized pharmacological prof...
Avalo Therapeutics price target raised to $40 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Avalo Therapeutics (AVTX) to $40 from $25 and keeps a Buy rating on the shares. The firm is “increasingly confident” heading into…
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune...
Avalo Therapeutics Transcript: Leerink Global Healthcare Conference 2026
AVTX-009, a selective anti-IL-1β antibody, completed a large phase II-B trial in HS with data expected in Q2 2025. The drug aims to surpass competitors by offering higher affinity, better dosing, and strong efficacy, with future expansion planned in validated inflammatory indications.
Avalo Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
AVTX-009, a high-affinity IL-1 beta antibody, is positioned for best-in-disease efficacy in HS, leveraging superior potency and trial rigor. Phase II data, expected soon, will inform rapid advancement to Phase III and broader market opportunities, with a differentiated safety profile and potential ancillary benefits.
Avalo Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
HS is a large, underdiagnosed market with rapid growth. AVTX-009, a high-affinity anti-IL-1β antibody, is positioned for differentiation through its mechanism, dosing, and safety. Phase II LOTUS trial data is expected next quarter, with phase III planning to follow.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i...